Lucentis And Stelara Biosimilars Drive Formycon’s 2024 Financials

As The Firm Finalizes US And EU Commercialization Partners For Eylea Biosimilar

 
• By Urtė Fultinavičiūtė
  
Half year results written on a keyboard key
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business